Partial
Mostly Aligned
Patient Risk:
Low
Summary
Only pharmacologic statements (beta-blocker activity) are supported by the provided label excerpts. Many claims are not addressed in the provided prescribing information (e.g., patent expiration, pricing, biosimilar/generic market rules), and safety/contraindication/warning/dosing sections were not evaluated against the label.
Category Scores
Accurate Statements
Coreg is a beta-blocker.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action (nonselective β-adrenergic blocking activity).
Unsupported Statements
Coreg (carvedilol) is a medication used to treat heart failure.
Not clearly supported from the provided label excerpt’s INDICATIONS AND USAGE (section 1 is not provided). Heart failure references appear only in other sections (e.g., 8.4/8.5 descriptions), so the claim is at best indirectly supported by the excerpts provided.
Coreg (carvedilol) is a medication used to treat high blood pressure.
The provided label excerpts do not include an explicit indication statement for hypertension; only mentions of 'hypertensive subjects' appear in 8.5. Indication/usage is not shown in the provided INDICATIONS AND USAGE section.
Coreg works by blocking the effects of epinephrine.
The provided label excerpt describes nonselective β-adrenoreceptor blocking activity but does not explicitly state that it 'blocks the effects of epinephrine.'
The patent for Coreg 3.125 mg, 6.25 mg, and 12.5 mg tablets expired on May 26, 2015.
Patent expiration dates and related legal/market facts are not provided in the supplied label sections.
The patent for Coreg 25 mg and 50 mg tablets expired on August 12, 2013.
Patent expiration dates are not provided in the supplied label sections.
Generic versions of Coreg have been available for years.
Availability of generics is not provided in the supplied label sections.
Multiple versions of generic Coreg are being manufactured and sold by generic drug makers.
Manufacturing/sales status of generic products is not provided in the supplied label sections.
Prices for generic Coreg can vary depending on the manufacturer and the dosage.
Pricing information is not provided in the supplied label sections.
On average, the price for a 30-day supply of generic Coreg 3.125 mg, 6.25 mg, and 12.5 mg tablets is around $10-$20.
Pricing estimates are not provided in the supplied label sections.
On average, the cost of generic Coreg 25 mg and 50 mg tablets is slightly higher at around $30-$50 for a 30-day supply.
Pricing estimates are not provided in the supplied label sections.
With the patent for Coreg expired, biosimilars cannot enter the market until a generic version of the medication's active ingredients enters the market.
Biosimilar vs generic market entry timing rules are not provided in the supplied label sections.
Biosimilars are not applicable to generic medications like Coreg.
Biosimilar applicability is not provided in the supplied label sections.
Contradictions
Important Omissions
Dose/administration details, titration, and any safety monitoring requirements (no claims made by the AI about these, but the audit cannot verify dosing alignment because the response provided none).
Importance:
Moderate
Contraindications/warnings/boxed warning alignment (the response made no statements but was not assessed against these label sections).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated response contains no dosing/safety instructions. However, multiple non-label legal/market statements are included, which are not prescribing-information claims and could mislead without affecting immediate medication safety directly.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many claims are not supported by the provided FDA label excerpts (especially patents, pricing, and biosimilar/generic market entry rules). Additionally, safety-critical label elements were not evaluated against the label.
Suggested Improvement
Restrict claims to label-supported content from the actual FDA sections provided (e.g., pharmacology and clearly documented indications). Remove or clearly separate non-label legal/market statements from the prescribing-information summary.